Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. (OBIO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
obio · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Orchestra BioMed Holdings, Inc.You OBIO | $237M | N/A | — | — |
 Avalo Therapeutics, Inc. AVTX | $149M | N/A | — | -$5.84 |
 Caribou Biosciences, Inc. CRBU | $182M | N/A | — | -$1.59 |
 Enanta Pharmaceuticals, Inc. ENTA | $266M | N/A | — | -$3.84 |
 Eupraxia Pharmaceuticals Inc. EPRX | $204M | N/A | — | -$1.35 |
 Inventiva S.A. IVA | $203M | N/A | — | -$1.82 |
 Invivyd, Inc. IVVD | $135M | N/A | — | -$0.30 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Orchestra BioMed Holdings, Inc. (OBIO) measures how much investors pay for each dollar of the company's trailing earnings. OBIO's current PE ratio of N/A is calculated by dividing its stock price of $3.95 by its TTM earnings per share of —.
Frequently asked questions
OBIO pe ratio · 6 questionsOBIO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.95 and TTM EPS of —. Data sourced from Financial Modeling Prep via OBIO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Orchestra BioMed Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09